Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails
American Journal of Nephrology · 2025
DOI: 10.1159/000546265 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Laibah Arshad Khan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Mississippi Medical Centre, Jackson, Mississippi, USA. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperphosphatemia, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Tenapanor is currently seen as a promising treatment for hyperphosphatemia in haemodialysis patients. Although previous meta-analysis has investigated its efficacy and safety, the potential impact of tenapanor remained a topic of further investigation. This meta-analysis aims to provide an updated and thorough assessment of tenapanor efficacy in reducing serum phosphate levels and its safety in haemodialysis patients, integrating new evidence and refining the analysis of treatment outcomes. Methodology: In this systematic review and meta-analysis, we searched online databases up to August 2024 for studies evaluating the efficacy and safety of tenapanor in haemodialysis patients. Only short-term randomized controlled trials (4 to 8 weeks) comparing tenapanor with placebo were included. The primary outcome was the change in serum phosphate levels from baseline. Safety was assessed based on data regarding drug-related adverse effects (AEs), including diarrhoea and other gastrointestinal AEs.
Results
Among the selected 8 clinical trails with a total of 1001 patients, tenapanor showed a significant reduction in serum phosphate levels from baseline compared to placebo (mean difference [MD] -1.39mg/dl, 95% CI: -1.94,0.84, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Mississippi Medical Centre, Jackson, Mississippi, USA.
- Rehman Medical College, Peshawar, Pakistan, bakhtawar.23a@gmail.com.
- Civil Hospital, Mīrpur Khās, Pakistan.
- Services Institute of Medical Sciences, Lahore, Pakistan.
- Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan.
- Alnafees Medical College, Islamabad, Pakistan.
Zitieren
APA
Khan, L. A., Alam, B., Ladhwani, N. K., Abid, H., Mazhar, Z., Gondal, S. U., Tufail, J., Zia, A., Naqvi, S. Z. E. Z., Saeed, M. U., Abideen, Z. U., Sahjwani, V., Lohana, O. K., Kumar, V., Ali, S., & Amjad, Z. (2025). Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails. American Journal of Nephrology. https://doi.org/10.1159/000546265
Vancouver
Khan LA, Alam B, Ladhwani NK, Abid H, Mazhar Z, Gondal SU, et al. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails. American Journal of Nephrology. 2025. doi:10.1159/000546265
BibTeX
@article{Khan2025,
author = {Khan, Laibah Arshad and Alam, Bakhtawara and Ladhwani, Naresh Kumar and Abid, Hamna and Mazhar, Zain and Gondal, Saim Umar and Tufail, Jawria and Zia, Ahmed and Naqvi, Syeda Zil E Zehra and Saeed, Muhammad Usama and Abideen, Zain Ui and Sahjwani, Vishaka and Lohana, Om Kumar and Kumar, Varoon and Ali, Saiyad and Amjad, Zainab},
title = {Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails},
journal = {American Journal of Nephrology},
year = {2025},
doi = {10.1159/000546265}
}
EUVIMED